What is the diagnosis and recommended treatment for a healthy adult with a visible worm‑like lesion on the foot after walking barefoot, possibly cutaneous larva migrans or myiasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cutaneous Larva Migrans: Diagnosis and Treatment

Diagnosis

This is cutaneous larva migrans (CLM), a hookworm larval infection acquired from contaminated soil or sand, presenting as a characteristic serpiginous, intensely pruritic rash that migrates 1-2 cm per day. 1

Clinical Features

  • Characteristic serpiginous (snake-like), raised, erythematous track that advances 1-2 cm daily, distinguishing it from other dermatoses 1
  • Intense pruritus that may prevent sleep, often leading to bacterial superinfection from scratching 2
  • Most commonly affects the feet (39% of cases), followed by buttocks (18%) and abdomen (16%) after barefoot contact with contaminated beaches or soil 3
  • Caused by dog and cat hookworm larvae (Ancylostoma braziliense and A. caninum) that penetrate human skin but cannot complete their life cycle 4, 2

Diagnostic Approach

  • Diagnosis is purely clinical based on the characteristic migratory rash and exposure history 1
  • Laboratory tests (eosinophil count, serology) are typically normal and not required 3
  • Eosinophilia may occasionally be present but is not a reliable diagnostic feature 1

Treatment Recommendations

Treat with oral ivermectin 200 μg/kg as a single dose OR albendazole 400 mg once daily for 3 days. 1

First-Line Oral Therapy

  • Ivermectin 200 μg/kg as a single dose achieves 81-100% cure rates and is the preferred option 1, 5
  • Albendazole 400 mg once daily for 3 days is an equally effective alternative, with cure rates of 77-100% 1, 3
  • Both agents are superior to topical therapy for multiple lesions or extensive disease 5

When to Consider Topical Therapy

  • Topical thiabendazole 10-15% cream applied 3 times daily for 10-15 days may be used for single, localized lesions but has limited efficacy (80% cure rate) 5, 3
  • Topical therapy requires prolonged application and is impractical for multiple lesions 5

Agents to Avoid

  • Do NOT use oral thiabendazole due to poor efficacy (68-84% cure rate with single dose) and poor tolerability compared to albendazole or ivermectin 5, 3
  • Cryotherapy (freezing the leading edge) rarely works and is not recommended 5

Treatment Monitoring and Follow-Up

Expected Response

  • Most patients (64%) are cured with a single treatment course, though 25% require a second course and 2% may need three courses 3
  • Median symptom duration before treatment is 8 weeks (range 1-104 weeks), but treatment accelerates resolution 3
  • The infection is self-limited; larvae eventually die within months even without treatment, but treatment is mandatory due to intense pruritus and risk of bacterial superinfection 4, 2

When to Retreat

  • If the rash continues to advance 7-10 days after treatment, repeat the same regimen 5, 3
  • Persistent itching without track advancement may represent healing inflammation rather than treatment failure 2

Prevention Counseling

Individual Protection

  • Avoid direct skin contact with potentially contaminated sand or soil, particularly on beaches in tropical regions 2
  • Wear protective footwear in endemic areas to prevent larval penetration 2, 6

Epidemiological Context

  • Most infections are acquired in Africa (32%), the Caribbean (30%), and Southeast Asia (25%) 3
  • 95% of patients have a history of beach exposure, making this the primary risk setting 3
  • Children playing barefoot are at particular risk in areas where dog and cat hookworms are endemic 6

Common Pitfalls to Avoid

  • Do not confuse CLM with "larva currens" (Strongyloides infection), which moves much faster (several millimeters per second vs. 1-2 cm per day) and typically affects the trunk, upper legs, and buttocks 1
  • Do not misdiagnose as tinea pedis or other fungal infections, which lack the characteristic advancing serpiginous track 7, 8
  • Do not order unnecessary laboratory tests; the diagnosis is clinical and eosinophilia is typically absent 3
  • Do not use inadequate treatment durations with albendazole; a full 3-day course is required for optimal efficacy 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of cutaneous larva migrans.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000

Research

Cutaneous larva migrans infection in the pediatric foot. A review and two case reports.

Journal of the American Podiatric Medical Association, 1998

Guideline

Treatment of Tinea Pedis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Aggressive Foot Fungus

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the most common cause of cutaneous larva migrans?
Can larva cutaneous migrans cause peeling of the hands?
What is the recommended treatment for cutaneous larva migrans in an adult weighing 130 pounds (approximately 59 kilograms)?
What is the recommended treatment for an otherwise healthy individual with cutaneous larva migrans?
What is the recommended treatment for larva migrans cutanea?
In a 65‑year‑old man (45 kg) with biopsy‑proven axillary Hodgkin lymphoma, severe pancytopenia (hemoglobin 7 g/dL, absolute neutrophil count 1,100/µL, platelets 38,000/µL), chronic obstructive pulmonary disease, chronic lung disease, hypothyroidism, and CT showing hepatomegaly and splenomegaly with multiple hypodense liver and spleen nodules, what is the next step in management?
Can nebivolol be used in patients with chronic kidney disease (CKD) and acute kidney injury (AKI), and what dose adjustments and monitoring are required?
What is the recommended management for pansinusitis with a suspected fungal component?
How should I evaluate and manage a patient with pansinus disease that may involve a fungal component, distinguishing allergic fungal sinusitis from invasive fungal sinusitis?
How should bronchiolitis be managed in infants and young children under two years, including indications for hospitalization and supportive care?
How are ovarian germ‑cell tumors in adolescents and women under 30 evaluated and managed, including staging, fertility‑preserving surgery, chemotherapy regimens, and follow‑up?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.